Susquehanna International Group
VRAX icon

Susquehanna International Group’s Virax Biolabs VRAX Stock Holding History

Susquehanna International Group’s Portfolio VRAX Stock Details VRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-60
Closed -$4.88K – 13383
2023
Q3 		$4.88K Buy
+60
New +$5.62K ﹤0.01% 11792

Other funds holding VRAX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Susquehanna International Group's VRAX Position: Q4 2023 in Review

Susquehanna International Group sold out of Virax Biolabs (VRAX) in Q4 2023, closing a stake of 60 shares — an estimated $4.88K sold.

Susquehanna International Group first reported a position in VRAX in Q3 2023 and held it in 1 quarter. The position peaked at $4.88K in Q3 2023. 4 funds tracked by Wall St. Rank hold VRAX as of Q4 2023.

  • Susquehanna International Group reported no remaining Virax Biolabs position as of Q4 2023 after selling out during the quarter.
  • Susquehanna International Group sold 60 Virax Biolabs shares in Q4 2023, an estimated $4.88K.
  • Susquehanna International Group first reported a position in Virax Biolabs in Q3 2023 and held it in 1 quarter.
  • Susquehanna International Group's Virax Biolabs position peaked at $4.88K in Q3 2023.
  • 4 funds tracked by Wall St. Rank held Virax Biolabs as of Q4 2023.

Based on Susquehanna International Group's 13F filing for Q4 2023, filed 14 Feb 2024.